Advances in colon-targeted nano-drug delivery systems: challenges and solutions

Arch Pharm Res. 2020 Jan;43(1):153-169. doi: 10.1007/s12272-020-01219-0. Epub 2020 Jan 27.

Abstract

Nano-drug delivery systems (NDDS) for colon-targeted drug delivery are an active area of research on local diseases affecting the colon, such as ulcerative colitis, Crohn's disease, colon cancer, and for the delivery of peptide or protein drugs and vaccinations. In particular, targeted nano-drug delivery to the colon is advantageous for colon-specific diseases because nanoparticles can accumulate in diseased parts, improve the efficacies of therapeutics, and enable localized treatments, which reduces systemic toxicity. However, there are many hurdles, such as burst drug release, enzyme and acidic degradation of drug and carrier in the stomach, pH variations, mucus entrapment, and systemic uptake in the upper small intestine, which could challenge and compromise the successful delivery of NDDS to the colon. With advancements in NDDS, it may be possible to overcome these challenges leading to efficient drug delivery for colon-specific disorders. This review describes a few of the potential colon-specific drug delivery areas and the challenges faced by colon-targeted orally administered delivery systems, and provides an updated summary of recent advances in the development of orally administered NDDS for colon targeting, and the future advances in this research.

Keywords: Colon-targeting; Colorectal cancer; Nano-drug delivery; Ulcerative colitis.

Publication types

  • Review

MeSH terms

  • Animals
  • Colonic Diseases / drug therapy*
  • Colonic Diseases / metabolism
  • Drug Carriers / administration & dosage
  • Drug Carriers / chemistry
  • Drug Delivery Systems*
  • Drug Liberation
  • Humans
  • Hydrogen-Ion Concentration
  • Nanoparticles / administration & dosage
  • Nanoparticles / chemistry*

Substances

  • Drug Carriers